TY - JOUR
T1 - Myo-inositol reduces ?-catenin activation in colitis
AU - Bradford, Emily M.
AU - Thompson, Corey A.
AU - Goretsky, Tatiana
AU - Yang, Guang Yu
AU - Rodriguez, Luz M.
AU - Li, Linheng
AU - Barrett, Terrence A.
N1 - Publisher Copyright:
© The Author(s) 2017.
PY - 2017/7/28
Y1 - 2017/7/28
N2 - AIM To assess Dietary myo-inositol in reducing stem cell activation in colitis, and validate p?-cateninS552 as a biomarker of recurrent dysplasia. METHODS We examined the effects of Dietary myo-inositol treatment on inflammation, p?-cateninS552 and pAkt levels by histology and western blot in IL-10-/- and dextran soDium sulfate-treated colitic mice. AdDitionally, we assessed nuclear p?-cateninS552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia. RESULTS In mice, p?-cateninS552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, p?-cateninS552 staining Discriminated ulcerative colitis patients with a history of LGD from those with benign Disease. CONCLUSION Enumerating crypts with increased numbers of p?- cateninS552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.
AB - AIM To assess Dietary myo-inositol in reducing stem cell activation in colitis, and validate p?-cateninS552 as a biomarker of recurrent dysplasia. METHODS We examined the effects of Dietary myo-inositol treatment on inflammation, p?-cateninS552 and pAkt levels by histology and western blot in IL-10-/- and dextran soDium sulfate-treated colitic mice. AdDitionally, we assessed nuclear p?-cateninS552 in patients treated with myo-inositol in a clinical trial, and in patients with and without a history of colitis-induced dysplasia. RESULTS In mice, p?-cateninS552 staining faithfully reported the effects of myo-inositol in reducing inflammation and intestinal stem cell activation. In a pilot clinical trial of myo-inositol administration in patients with a history of low grade dysplasia (LGD), two patients had reduced numbers of intestinal stem cell activation compared to the placebo control patient. In humans, p?-cateninS552 staining Discriminated ulcerative colitis patients with a history of LGD from those with benign Disease. CONCLUSION Enumerating crypts with increased numbers of p?- cateninS552 - positive cells can be utilized as a biomarker in colitis-associated cancer chemoprevention trials.
KW - Biomarker
KW - Chemoprevention
KW - Colitis-associated cancer
KW - Dysplasia
KW - Stem cell
UR - http://www.scopus.com/inward/record.url?scp=85026503516&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85026503516&partnerID=8YFLogxK
U2 - 10.3748/wjg.v23.i28.5115
DO - 10.3748/wjg.v23.i28.5115
M3 - Article
C2 - 28811707
AN - SCOPUS:85026503516
SN - 1007-9327
VL - 23
SP - 5115
EP - 5126
JO - World Journal of Gastroenterology
JF - World Journal of Gastroenterology
IS - 28
ER -
